Loading
Life sciences · Journal article
Journal of Nanobiotechnology · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Immune checkpoint blockade has improved cancer treatment outcomes, yet many solid tumors remain immunologically “cold” and resistant to therapy. Tertiary lymphoid structures (TLSs) are linked to enhanced survival and response rates, but germinal center-like TLSs are challenging to generate in subcutaneous tumors due to rapid clearance of soluble inductive signals. We engineered an injectable supramolecular hydrogel to co-deliver liposome-formulated mRNAs encoding CXCL13 and LIGHT, thereby stabilizing the complexes and extending intratumoral cytokine production. In murine B16.f10, CT26, and 4T1 subcutaneous tumor models, this strategy increased TLS density and maturation, suppressed tumor growth, and prolonged survival. Combination with PD-1 blockade yielded enhanced efficacy antitumor effects, achieving complete tumor regression in some cases. Our results support the development of a novel injectable hydrogel-encapsulated formulation in combination with liposomes for enhancing the efficacy of mRNA therapeutics against cancer.